TriSalus Life Sciences Inc. Asset Resilience Ratio
TriSalus Life Sciences Inc. asset resilience ratio. TriSalus Life Sciences Inc. (TLSI) has an Asset Resilience Ratio of 24.20% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TriSalus Life Sciences Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TriSalus Life Sciences Inc. (None–None)
Asset resilience ratio of TriSalus Life Sciences Inc. from None to None. This chart shows how TriSalus Life Sciences Inc.'s Asset Resilience Ratio has changed over time. Read TriSalus Life Sciences Inc. (TLSI) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TriSalus Life Sciences Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TLSI asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $60.60 Million | 24.2% |
| Total Liquid Assets | $60.60 Million | 24.20% |
Asset Resilience Insights
- Good Liquidity Position: TriSalus Life Sciences Inc. maintains a healthy 24.20% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
TriSalus Life Sciences Inc. Industry Peers by Asset Resilience Ratio
Compare TriSalus Life Sciences Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
TriSalus Life Sciences Inc. Asset Resilience Ratio by Year (None–None)
TriSalus Life Sciences Inc. asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for TriSalus Life Sciences Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more